YolTech Secured $15 Million in Series A+ Financing

Nov. 2023, Shanghai - YolTech Therapeutics Co., Ltd. (“YolTech” or “Company”) an innovative biotech company pioneering in-vivo gene editing technologies and lipid nanoparticles (LNPs) platform, announced the successful completion of $15 million Series A Plus financing. Decheng Capital led this investment, with other new investors including Guangzhou Industrial Investment and Hofon Capital. Previously the company completed a Series A Financing of $17 million in August 2022, led by Grand Flight, with participation from K2VC, Yunion Healthcare Ventures, and Unity Ventures. The total $32 million financing will support advancement of YolTech's therapeutic programs toward the clinic, and continued investment in the company's core editing platform.

YolTech stands out globally leading level of CRISPR/Cas and base editing tools and established a noval high-throughput gene editing evolution platform as well as in-house GMP manufacturing for LNP deliver system. YolTech proprietary Cas enzymes, base editors, and LNPs-have strong IP protection, ensuring the freedom to implement patents worldwide.

YolTech pipeline targets a variety of clinical needs globally, covering genetic diseases, metabolic disorders, and infectious diseases. YOLT-201，as YolTech's leading in vivo gene editing drug candidate, has completed toxicology and pharmacology studies, showing promising potential of safety and efficacy profile in large animal trials. The in vivo editing efficiency with single administration has achieved best-in-class potential. Recently, YolTech submitted the IND application for YOLT-201 to the National Medical Products Administration, paving the way for the first registered clinical trial in China for an in vivo gene editing drug based on the mRNA-LNP delivery system.

About YolTech

YolTech is a pioneering gene editing company dedicated to developing a robust gene editing medicines to treat patients with serious diseases. The company has a rare high-throughput gene editor evolution platform in China. At present, the company's three major technology platforms, Cas enzyme, base editor and lipid nanoparticles (LNP), all have independent intellectual property rights and core patent protection, which can ensure that patents are Free implementation worldwide.